If you enjoy this content, please share it with a colleague
Sapheneia
RELATED CONTENT
September 7, 2017 — Sapheneia and Scannerside received U.S. Food and Drug Administration (FDA) 510(k) clearance to ...
Less than 30 days after the Sapheneia Scannerside partnership announcement, the two companies released CMS Lung Screening, ClearCT Lung.
Sapheneia has partnered with Scannerside to provide a comprehensive dose strategy (CDS) to the medical imaging industry.
Management of Sapheneia LLC and Sapheneia Commercial Products AB won the final two cases in Swedish Appeals Court.
Radiation dose management has come to the forefront of healthcare concerns with both patients and providers advocating for measures that will decrease and manage exposure. Research has shown that medical imaging has doubled the public’s exposure to ionizing radiation since the 1980s, and while this statistic includes fluoroscopy, angiography, mammography and standard X-ray, computed tomography (CT) has contributed the majority of the dose increase.
Sapheneia Commercial Products AB filed for bankruptcy Aug. 28, 2013. Shortly before the company went into bankruptcy, it changed its company name to “Contact Imaging Sweden AB.” In July 2013, the Stockholm District Court ruled that ContextVision is the real owner of a key patent application filed by Sapheneia in September 2006. The court also ruled that Sapheneia should pay the legal costs of ContextVision amounting to TSEK 2,940. The amount has not been paid, and instead, Sapheneia filed for bankruptcy. The administration of the company in bankruptcy has been taken over by a receiver.
The issue of ionizing radiation in medical imaging is often discussed and is a hotly debated topic. Computed tomography (CT) is the major contributor to medical radiation dose exposure and has been vilified in lay and professional press as a danger to those exposed, potentially carcinogenic and most dangerous in children. As a pediatric radiologist, my primary concern is in producing high-quality diagnostic images with radiation dose as low as reasonably achievable (ALARA).
The Stockholm District Court ruled ContextVision is the owner of a patent application filed by Sapheneia in September 2006. The patent application represents the underlying technology across multiple medical imaging modalities. ContextVision proved that the technology within the patent is a result of work the two filing inventors conducted during their time at ContextVision.
September 28, 2010 – Three new customers have joined a growing list of hospitals, imaging centers and clinics that use the Clarity CT solution to enable material reductions in the medical radiation exposed to patients. They are: Watson Clinic of Lakeland, Fla.; Zilkha Radiology of East Islip, N.Y., and Inova Alexandria Hospital of Alexandria, Va.